Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
AMT-253 by Multitude therapeutics for Metastatic Melanoma: Likelihood of Approval
AMT-253 is under clinical development by Multitude therapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...
AMT-253 by Multitude therapeutics for Solid Tumor: Likelihood of Approval
AMT-253 is under clinical development by Multitude therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
AMT-151 by Multitude therapeutics for Malignant Pleural Mesothelioma: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Malignant Pleural Mesothelioma. According to GlobalData,...
AMT-116 by Multitude therapeutics for Liver Cancer: Likelihood of Approval
AMT-116 is under clinical development by Multitude therapeutics and currently in Phase I for Liver Cancer. According to GlobalData, Phase...
AMT-116 by Multitude therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma): Likelihood of Approval
AMT-116 is under clinical development by Multitude therapeutics and currently in Phase I for Basal Cell Carcinoma (Basal Cell Epithelioma)....
AMT-116 by Multitude therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
AMT-116 is under clinical development by Multitude therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
AMT-116 by Multitude therapeutics for Bladder Cancer: Likelihood of Approval
AMT-116 is under clinical development by Multitude therapeutics and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...
AMT-116 by Multitude therapeutics for Gastric Cancer: Likelihood of Approval
AMT-116 is under clinical development by Multitude therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
AMT-116 by Multitude therapeutics for Pancreatic Cancer: Likelihood of Approval
AMT-116 is under clinical development by Multitude therapeutics and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
AMT-116 by Multitude therapeutics for Head And Neck Cancer: Likelihood of Approval
AMT-116 is under clinical development by Multitude therapeutics and currently in Phase I for Head And Neck Cancer. According to...
AMT-116 by Multitude therapeutics for Colorectal Cancer: Likelihood of Approval
AMT-116 is under clinical development by Multitude therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
AMT-116 by Multitude therapeutics for Cervical Cancer: Likelihood of Approval
AMT-116 is under clinical development by Multitude therapeutics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...
AMT-151 by Multitude therapeutics for Epithelial Ovarian Cancer: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...
AMT-151 by Multitude therapeutics for Lung Adenocarcinoma: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Lung Adenocarcinoma. According to GlobalData, Phase...
AMT-151 by Multitude therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
AMT-151 by Multitude therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
AMT-151 by Multitude therapeutics for Peritoneal Cancer: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase...
AMT-151 by Multitude therapeutics for Endometrial Cancer: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
AMT-151 by Multitude therapeutics for Fallopian Tube Cancer: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...
AMT-116 by Multitude therapeutics for Esophageal Cancer: Likelihood of Approval
AMT-116 is under clinical development by Multitude therapeutics and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...